Europe is witnessing a ‘pharmaceutical war’ at the expense of the vaccine and the secondary effects it causes. A battle for the credibility of each manufacturer that, for the moment, loses the Oxford University and AstraZeneca after its application has been widely suspended in the European Union. In Spain a suspicious death is already being investigated. However, from the United Kingdom the focus is also on the competitors of its homeland vaccine: the Ministry of Health British notes that it has registered up to 26 deaths from heart failure and heart attacks in patients who had received doses of Pfizer.
Are the coronavirus vaccines being applied around the world safe? According to international authorities on the matter, such as the World Health Organization (OMS) o la European Medicines Agency, Yes. However, the stoppage of AstraZeneca vaccine inoculation in a dozen countries in the European Union (including Spain), who investigate the relationship of these doses with episodes of cerebral thrombosis, has stoked doubts.
In the background there is an all-out war between pharmaceutical companies competing in the same market to place their product. And in the midst of this scenario, the Regulatory Agency for Medicines and Health Products, dependent on the British Ministry of Health, has published a series of reports on the adverse side effects that it has detected in vaccines of AstraZeneca and of Pfizer. The two that it is currently inoculating, with more than 10 million doses each given to the British.
The side effects under study of the Pfizer vaccine, outside of the exclusive focus that has been placed on AstraZeneca, are striking: British health authorities are investigating at least 26 deaths from heart disorders in patients who had received their dose of the American drug. Of these, 15 were due to heart failure, one more cardiorespiratory, one pericarditis, 6 heart attacks of myocardium and the rest due to various conditions related to the coronary arteries.
Thrombi, sudden deaths
Also noted in those reports, which are updated weekly, a total of 14 sudden deaths in patients who received Pfizer. Another 24 due to thrombi. It does not assume a direct link or even any proof of causation, but is merely a statistical record. The figures he attributes to the AstraZeneca vaccine are similar.
In total, the UK has accounted for a total of 94,809 reactions of all kinds in people who were vaccinated with Pfizer (with no evidence that it is because of it), of which 227 ended in fatal outcome. In the case of AstraZeneca, the figures amount to 201,622 reactions, with 275 cases of suspicious deaths.
The WHO and the EMA insist on explaining that these figures are not alarming in themselves, since they are incidences similar to those that occur in the unvaccinated population and that, for now, there is no proof for the vaccine to cause these serious effects.
Health stops vaccination
Meanwhile, Spain remains awaiting the key meeting of the European Medicines Agency, which this Thursday plans to offer its conclusions after studying the cases of post-vaccination thrombi that have been transmitted to it by the countries of the Union.
In the official Health information note announcing the stoppage of vaccination with AstraZeneca to the autonomous health systems, the department of Carolina Darias explains that “last week, the Austrian and Danish health authorities preventatively immobilized a batch of AstraZeneca vaccine after reporting serious adverse events related to thrombotic events no more frequent than expected in the general population. Some European countries joined this measure.
«The Spanish Agency for Medicines and Health Products (AEMPS) last Friday, March 12, the Committee for the Evaluation of Pharmacovigilance Risks (PRAC) of the European Medicines Agency (EMA), considered that the benefits of the vaccine continued to outweigh the risks and it could continue to be administered while the evaluation of related events in this regard was being completed, “they explain from the Dairas department.
However, they assure, “throughout Saturday and Sunday (March 13 and 14), some notifications have been received (one of them in Spain) of a specific type of thrombotic event. Is about cerebral venous sinus thrombosis associated with a decrease in the number of platelets in the blood (thrombocytopenia) and which are very rare in the general population ”. “At the present time, the cases do not appear to be associated with a specific batch,” the document specifies.